Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 19, 2026, 1:39 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: oxycodone 20 mg Clear all
Completed Phase 4 Interventional Results available

Analgesia After Total Knee Arthroplasty: Peri-Articular Injection Versus Epidural + Femoral Nerve Blockade

NCT01335542
View directory record Official record
Conditions
Readiness to Discharge
Interventions
Peri-Articular Injection, Epidural Pathway (PCEA+FNB)
Procedure
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years to 85 Years
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 13, 2022 · Synced Sep 19, 2026, 1:39 AM EDT
Terminated Phase 3 Interventional Results available

Safety and Efficacy of Buprenorphine Transdermal System (BTDS) in Subjects With Moderate to Severe Osteoarthritis Pain

NCT00312221
View directory record Official record
Conditions
Osteoarthritis
Interventions
Buprenorphine, oxycodone immediate-release
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
40 Years and older
Enrollment
418 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
23
States / cities
Birmingham, Alabama • Chula Vista, California • Roseville, California + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2012 · Synced Sep 19, 2026, 1:39 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of PF614 Compared to OxyContin® in Healthy Volunteers (PF614-101)

NCT02454712
View directory record Official record
Conditions
Healthy
Interventions
PF614, Oxycodone extended-release, Naltrexone Hydrochloride
Drug
Lead sponsor
Ensysce Biosciences
Industry
Eligibility
18 Years to 50 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Sep 19, 2026, 1:39 AM EDT
Completed Phase 3 Interventional Results available

Long-Term Safety of Twice Daily Oxycodone Hydrochloride Controlled-release Tablets in Children Who Completed OTR3001

NCT01369615
View directory record Official record
Conditions
Pain
Interventions
Oxycodone hydrochloride controlled-release tablets
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
6 Years to 17 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
13
States / cities
Birmingham, Alabama • Paramount, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2015 · Synced Sep 19, 2026, 1:39 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study of Ketorolac Versus Opioid for Pain After Endoscopy

NCT03888144
View directory record Official record
Conditions
Kidney Calculi, Ureteral Calculi
Interventions
Oxycodone, Ketorolac
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Sep 19, 2026, 1:39 AM EDT
Terminated Phase 3 Interventional Results available

Safety and Efficacy of Buprenorphine Transdermal System (BTDS) in Subjects With Moderate to Severe Low Back Pain

NCT00313014
View directory record Official record
Conditions
Back Pain Lower Back Chronic
Interventions
Buprenorphine, Oxycodone Immediate-Release
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
18 Years and older
Enrollment
660 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
85
States / cities
Birmingham, Alabama • Haleyville, Alabama • Phoenix, Arizona + 72 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2012 · Synced Sep 19, 2026, 1:39 AM EDT
Terminated Phase 4 Interventional Results available

Measuring Gait And Self-Reported Pain In Patients With Osteoarthritis Of The Knee Using Placebo/Oxycodone/Celecoxib.

NCT00484718
View directory record Official record
Conditions
Osteoarthritis
Interventions
celecoxib, Oxycodone, placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
40 Years to 70 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
2
States / cities
Palo Alto, California • Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 13, 2021 · Synced Sep 19, 2026, 1:39 AM EDT
Not listed Phase 4 Interventional

Pain Relief After Hiatal Hernia Repair Surgery

NCT04936711
View directory record Official record
Conditions
Shoulder Pain, Hiatal Hernia
Interventions
Resteck Shiatsu Neck and Back Massager, Marcaine
Device · Drug
Lead sponsor
Norton Thoracic Institute
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 22, 2021 · Synced Sep 19, 2026, 1:39 AM EDT
Completed Phase 4 Interventional Results available

Study of EXPAREL in Patients Undergoing Breast Augmentation

NCT01582490
View directory record Official record
Conditions
Mammoplasty, Postoperative Pain
Interventions
Instillation - EXPAREL, Infiltration - EXPAREL
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 75 Years · Female only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Brighton, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 1, 2014 · Synced Sep 19, 2026, 1:39 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Dose Proportionality Study Of PF-00345439 Formulation Under Fed Conditions

NCT02089295
View directory record Official record
Conditions
Healthy
Interventions
Oxycodone
Drug
Lead sponsor
Pain Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
2
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 3, 2016 · Synced Sep 19, 2026, 1:39 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Abuse Potential of Gabapentin Taken Orally Concomitantly With Oxycodone Hydrochloride in Healthy, Non-Drug-Dependent, Recreational Opioid Users

NCT07813026
View directory record Official record
Conditions
Healthy, Non-Drug- Dependent, Recreational Opioid Users
Interventions
Placebo, Oxycodone 20mg, gabapentin 600 mg, Gabapentin 1200mg, Gabapentin 600 mg + Oxycodone 20 mg, Gabapentin 1200 mg + Oxycodone 20 mg
Drug
Lead sponsor
Viatris Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Sep 19, 2026, 1:39 AM EDT
Completed Phase 4 Interventional Results available

Hydrocodone For Pain Control in First Trimester Surgical Abortion

NCT01330459
View directory record Official record
Conditions
Pain
Interventions
Hydrocodone/acetaminophen, Placebo, Ibuprofen, Lorazepam, Lidocaine
Drug
Lead sponsor
Elizabeth Micks
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
2
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 25, 2019 · Synced Sep 19, 2026, 1:39 AM EDT
Completed Phase 3 Interventional Results available

Safety Study of Oxycodone Hydrochloride and Naltrexone Hydrochloride Extended-Release Capsules in Subjects With Moderate to Severe Chronic Noncancer Pain

NCT01428583
View directory record Official record
Conditions
Chronic Noncancer Pain
Interventions
oxycodone HCl and naltrexone HCl extended-release capsules
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
395 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
32
States / cities
DeLand, Florida • Jacksonville, Florida • Jupiter, Florida + 27 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2016 · Synced Sep 19, 2026, 1:39 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Educational Video on Pain Management and Subsequent Opioid Use After Cesarean Delivery

NCT03959969
View directory record Official record
Conditions
Opioid Use, Unspecified
Interventions
Educational video, Standard of care, Ibuprofen, Oxycodone
Other · Drug
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 31, 2021 · Synced Sep 19, 2026, 1:39 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Too Much of a Good Thing? Impact of Initial Prescription Size in Post-cesarean Section Pain Management

NCT05360433
View directory record Official record
Conditions
Post Operative Pain
Interventions
Oxycodone oral capsule
Drug
Lead sponsor
Carilion Clinic
Other
Eligibility
19 Years to 40 Years · Female only
Enrollment
170 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Roanoke, Virginia
Source: ClinicalTrials.gov public record
Updated May 3, 2022 · Synced Sep 19, 2026, 1:39 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Characterize the Abuse Liability of Intravenous Oxycodone Alone or in Combination With Intravenous Naltrexone in Healthy, Non-Dependent, Recreational Opioid Users

NCT01825447
View directory record Official record
Conditions
Healthy
Interventions
Placebo, Oxycodone + Naltrexone, Oxycodone
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
89 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 7, 2013 · Synced Sep 19, 2026, 1:39 AM EDT
Completed Phase 3 Interventional

The Safety and Efficacy of the Buprenorphine Transdermal Delivery System in Subjects With Chronic Low Back Pain.

NCT00315874
View directory record Official record
Conditions
Back Pain
Interventions
Buprenorphine transdermal delivery system
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
18 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 1998
U.S. locations
12
States / cities
Phoenix, Arizona • Gainesville, Florida • Plantation, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated May 13, 2013 · Synced Sep 19, 2026, 1:39 AM EDT
Recruiting Phase 4 Interventional

Comparing Analgesic Regimen Effectiveness and Safety for Surgery (CARES) Trial

NCT05722002
View directory record Official record
Conditions
Surgery, Pain, Postoperative
Interventions
NSAID, Opioid, Acetaminophen
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
6
States / cities
Ann Arbor, Michigan • Detroit, Michigan • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 19, 2026, 1:39 AM EDT
Completed Phase 1 Interventional Results available

Pharmacokinetics and Safety of ORF Tablets in Pediatric Patients

NCT01160614
View directory record Official record
Conditions
Opioid Analgesia
Interventions
Oxycodone hydrochloride controlled-release (ORF) tablets
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
6 Years to 16 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
13
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Palo Alto, California + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2012 · Synced Sep 19, 2026, 1:39 AM EDT
Completed Phase 1 Interventional Results available

Prescription Medication Interactions

NCT04315181
View directory record Official record
Conditions
Opioid Use, Sedative Use
Interventions
Opioid Agonist, Sedatives
Drug
Lead sponsor
Sharon Walsh
Other
Eligibility
18 Years to 55 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 19, 2025 · Synced Sep 19, 2026, 1:39 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Randomized, Two-way, Crossover Study to Estimate the Relative Bioavailability of a Controlled-release Formulation of Oxycodone (40 mg) With Sequestered Naltrexone Compared With Immediate-release Oxycodone Tablets (20 mg) in Healthy Volunteers

NCT01677065
View directory record Official record
Conditions
Healthy
Interventions
Oxycodone controlled-release test formulation, Immediate-release reference drug
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 27, 2018 · Synced Sep 19, 2026, 1:39 AM EDT
Terminated Phase 3 Interventional Results available

A Long-term Safety Study With Tapentadol ER and Oxycodone CR in Patients With Moderate to Severe Pain Due to Chronic, Painful Diabetic Peripheral Neuropathy (DPN)

NCT01063868
View directory record Official record
Conditions
Diabetic Neuropathy, Painful, Diabetic Polyneuropathy
Interventions
Tapentadol extended release (ER), Oxycodone controlled release (CR)
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
23
States / cities
Mesa, Arizona • Tucson, Arizona • Fruitland Park, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2014 · Synced Sep 19, 2026, 1:39 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Oxycodone/Naloxone Controlled-release Tablets (OXN) Compared to Placebo in Opioid-experienced Subjects With Moderate to Severe Chronic Low Back Pain

NCT01358526
View directory record Official record
Conditions
Low Back Pain
Interventions
Oxycodone/Naloxone Controlled-release, Placebo
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
18 Years and older
Enrollment
1,095 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
151
States / cities
Birmingham, Alabama • Haleyville, Alabama • Huntsville, Alabama + 123 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2015 · Synced Sep 19, 2026, 1:39 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Determine the Effects of Co-Administration of Alcohol on the Absorption of Oxycodone From a Proprietary Controlled-Release Formulation

NCT01677039
View directory record Official record
Conditions
Healthy
Interventions
Test formulation administered with water, Test formulation administered with 20% ethanol, Test formulation administered with 40% ethanol
Drug
Lead sponsor
Pfizer
Industry
Eligibility
21 Years to 55 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 10, 2012 · Synced Sep 19, 2026, 1:39 AM EDT